Evaluation of Biomarkers of Atopic Dermatitis in Pediatric Patients (PEDISTAD BIOMARKER STUDY)
← catalyst calendarSponsored by Sanofi (industry) · SNY — their whole pipeline →.
Phase
—
Status
Completed
Study type
Observational
Enrollment
266actual
Sites
48
Countries
Argentina, Australia, Brazil +6
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2019-04-05 | actual | When the study began enrolling |
| Primary completion | 2026-04-20 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2026-04-20 | actual | The whole study's end, after follow-up |
| First posted | 2019-02-21 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-07-06 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Dermatitis Atopic
Interventions
- Other: Blood sample
- Other: Cheek swab
Primary outcomes
what the primary-completion date above is the date OFBiomarker identification: Demographics
measured Baseline
Biomarker identification: Baseline disease characteristics
measured Baseline
Biomarker identification: Changes in disease severity
measured Up to 5 years
Biomarker evaluation: High versus low disease severity across participants
measured Up to 5 years
Biomarker identification: New presentation or resolution of atopic comorbidity
measured Up to 5 years
Biomarker identification: Introduction of new systemic treatment
measured Up to 5 years
Biomarker identification: Response to systemic treatment
measured Up to 5 years
Biomarker identification: Loss of response to systemic treatment
measured Up to 5 years
Biomarker evaluation: Start of systemic therapy early in life versus later in life
measured Up to 5 years
Permalink · SNY's whole pipeline · Catalyst calendar · Every registered study · What changed